Casos Clínicos
Cardiac Amyloidosis, Follow the Trail Not to Miss the Diagnosis
Conteúdo principal do artigo
Silvia Ribeiro
Filipa Cordeiro
João Costa
Resumo
A amiloidose é uma doença sistémica causada pelo depósito extracelular de fibrilas insolúveis de proteínas de baixo peso molecular, sendo as mais comuns as cadeias leves (amiloidose AL) e a transtirretina (amiloidose ATTR), esta última sob a forma adquirida (wild type) ou hereditária. Apesar de ser considerada rara, é hoje reconhecido o seu subdiagnóstico, pelo que é fundamental um elevado índice de suspeita no sentido de alterar a morbilidade e mortalidade dos doentes por ela afetados.
Os autores descrevem um caso clínico de amiloidose com envolvimento cardíaco.
Detalhes do artigo
Este trabalho encontra-se publicado com a Creative Commons Atribuição-NãoComercial 4.0.
Referências
Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44:3503-626. doi: 10.1093/eurheartj/ehad194.
Writing Committee; Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81:1076-126. doi: 10.1016/j.jacc.2022.11.022. Erratum in: J Am Coll Cardiol. 2023;81:1135. doi: 10.1016/j.jacc.2023.02.013.
Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585–94. doi:10.1093/eurheartj/ehv338.
Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879–87. doi.org/10.1093/eurheartj/ehx350.
Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Adv Ther. 2015;32:920-8. doi: 10.1007/s12325-015-0250-0.
Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. 2019;140:16-26. doi: 10.1161/CIRCULATIONAHA.118.038169.
Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40:232-9. doi: 10.1080/07853890701842988.
Cornwell GG 3rd, Murdoch WL, Kyle RA, Westermark P, Pitkänen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983;75:618-23. doi: 10.1016/0002-9343(83)90443-6.
Quarta CC, Zheng J, Hutt D, Grigore SF, Manwani R, Sachchithanantham S, et al. 99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2021;22:1304-11. doi: 10.1093/ehjci/jeab095.
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554–68. doi. org/10.1093/eurheartj/ehab072.
Maestro-Benedicto A, Vela P, de Frutos F, Mora N, Pomares A, Gonzalez-Vioque E, et al. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy. Eur J Heart Fail. 2022;24:2367-73. doi: 10.1002/ejhf.2658.
Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42:3427-520. doi: 10.1093/eurheartj/ehab364.
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379:1007-16. doi: 10.1056/NEJMoa1805689.
